A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 219
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : ATV
Long Form : atazanavir
No. Year Title Co-occurring Abbreviation
2019 Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis. CIs, ORs, UGT1A1
2019 Concomitant use of Cotrimoxazole and Atazanavir in HIV-infected patients: A Therapeutic Drug Monitoring and Pharmacovigilance based dual approach. AOR, aROR, DDI, PV, TDM
2019 Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility. LPV, RC
2019 Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients. RTV
2019 Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients. ---
2018 A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair. GWAS, SNPs
2018 Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice. ARV, HIV-1, nanoATV, PIs, RTV
2018 Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. ART, CPQA, MRM, QC
2018 Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. ARV, COBI, DRV, DTG, EFV, EVG, HCV, HIV, LPV, PK, RAL, RPV, RTV, SOF/VEL, TAF, TDF
10  2018 HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis. LPV/RTV, NO
11  2018 HIV-1 Protease Evolvability Is Affected by Synonymous Nucleotide Recoding. DRV, HIV-1, PBMCs, PI, PIs, WT
12  2018 Identification of Mechanism and Pathway of the Interaction between the African Traditional Medicine, Sutherlandia Frutescens, and the Antiretroviral Protease Inhibitor, Atazanavir, in Human Subjects Using Population Pharmacokinetic (PK) Analysis. PI, PK, SF
13  2018 Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States. ART, CNS, CSF, HIV, OR, VL
14  2018 Modulating cellular autophagy for controlled antiretroviral drug release. ARV, HBC
15  2018 Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults. NRTIs, PK, RTV, SGC
16  2018 Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies. CCQs
17  2018 Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial. AEs, MODAt
18  2018 Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study. EFV, HIVpt, SUSHI
19  2018 Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice. ABC, ART, COBI, DRV, DTG, EVG, FDC, HIV, INSTI, RPV, STRs, TAF, TDF
20  2018 Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in NonhumanPrimates. DcNPs, LPV, TLC-ART 101
21  2017 Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002). HIV-1, RTV, SOC
22  2017 Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial. AEs, CI, COBI, ORs, RTV
23  2017 Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. NHS, NRTIs
24  2017 Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir. ---
25  2017 Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF. eGFR, TDF, VL
26  2017 Highly active antiretroviral therapy dysregulates proliferation and differentiation of human pre-adipocytes. GPDH, NNRTIs, NRTIs, PIs, RTV
27  2017 Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele. cART, RIT, UGT
28  2017 Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. DRV, eGFR, LPV
29  2017 Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring? AAG, Ct, Cu, IQR, TDM
30  2017 Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery. ATV-2-NSA, ATV-Doc, PK, SEDDS, TK
31  2017 Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. EFV
32  2017 Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo. BW, FBG, FPI, IRS-1, SQV
33  2017 Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients. OD, RTV
34  2017 Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. cART, HR, HR
35  2017 The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy. FGT, HIV, mCT, TFV
36  2016 Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. BOC, RAL, SVR24
37  2016 Antiretrovirals inhibit arginase in human microglia. ARG, ARVs, DRV, EFV, nor-NOHA, NVP
38  2016 Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review. CIMT, CV, CVD, HIV, MI
39  2016 Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal. CCD, IVIVC, OPT, SPIP
40  2016 Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations. ASDs, LLPS, LPV, RTV
41  2016 Effects of antiretroviral treatment on paraoxonase 1 (PON1) activity in rats. HAART, PIs, PON1, RTV, SQV
42  2016 Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. DRV, eGFRCG
43  2016 Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function. eGFR, TDF
44  2016 Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients. ---
45  2016 Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study. CI, HR, pVL, VF
46  2016 Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting. ART, DRV, HIV, PDC, PPPM
47  2016 Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients. RTV
48  2016 Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy. ART, CI, EFV, Lp-PLA2, MPO, OS, oxLDL, UGT1A1
49  2016 Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study. CV, IR
50  2016 Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand. AE, ALT, ART, DAIDS, DRV, PY
51  2016 Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice. RAL
52  2016 Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy. AUC, EFV, EN, IM, RTV
53  2016 Transport-Metabolism Interplay of Atazanavir in Rat Hepatocytes. ---
54  2016 Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia. ART, CI, HR, TAM, VF
55  2015 A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. AUC, Cmax, COBI, FDC
56  2015 Adherence among rural HIV-infected patients in the deep south: a comparison between single-tablet and multi-tablet once-daily regimens. ADAP, ART, ARV, EFV, MTR, OR, PI, RTV
57  2015 Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: the role of NF-kappaB and PPAR-gamma. LPV/RTV
58  2015 Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types. ARV, DRV, MPRs, RAL
59  2015 Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. aHR, ARVs, CI, ddI, EFV, HIV, HR
60  2015 Different origin of adipogenic stem cells influences the response to antiretroviral drugs. AGPAT2, CEBPalpha, EFV, FABP4, FASN, LD, MSCs, NRTIs, PIs, PLIN1, PPARgamma, RTV
61  2015 Herb-drug interaction between an anti-HIV Chinese herbal SH formula and atazanavir in vitro and in vivo. HAART
62  2015 Infant peripheral blood repetitive element hypomethylation associated with antiretroviral therapy in utero. cART
63  2015 Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A. AE, cpm, RTV, TC, ULN
64  2015 Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure. ARV, Bayley-III, CDI
65  2015 Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects. AEs, AUCtau, BID, RTV
66  2015 Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients. ---
67  2015 PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naive and -experienced infants and children aged ≥3 months to <6 years. AEs, ARV, NRTI, RTV
68  2015 Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen. CVL, RAL, TDF/FTC
69  2015 Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis. ---
70  2015 Renal tubular disease in the era of combination antiretroviral therapy. ART, IDV, RTD
71  2015 Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens. ART, eGFR, HIV
72  2015 The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART Regimens. ART, Cr, DRV, HAART, INSTI, LPV, NNRTI, NRTI, TDF
73  2015 The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane. TdP
74  2015 [Highlights of the third edition of Chinese guidelines for AIDS diagnosis and treatment(2015)]. ART, RPV
75  2014 Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study. ---
76  2014 Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment. AEs, COBI, CrCl, DRV, PIs, RTV
77  2014 Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy. ART, BR, CoRIS, EFV, HCV/HBV, Lp-PLA2, MPO, OS, oxLDL
78  2014 Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. CI, CSF, DRV, IC50, PIs
79  2014 Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. CI, RAL
80  2014 Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients. RAMs
81  2014 Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. ART, MDM, nanoART
82  2014 Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. DRV, HIV, LNPs, RTV, TFV
83  2014 Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens. ---
84  2014 HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle. ART, CI, HIV, TFV
85  2014 Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. ALDH, ARV, DETC-MeSO, DIS, DIS carbamate, EFV, RTV
86  2014 Metronidazole or Cotrimoxazole therapy is associated with a decrease in intestinal bioavailability of common antiretroviral drugs. CTX, MTZ, RTV
87  2014 Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens. PIs, PS
88  2014 No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting. ART, DRV, HIV, PIs
89  2014 Optimized self-nanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in vitro/in vivo characterization. OPT, SNEDDS
90  2014 Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018. ABC, DRV, EFV
91  2014 Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts. DRV, EFV, LPV, MNC, RTV
92  2014 Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir. HCV, HIV, RTV, TVR
93  2014 Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. AEs, ART, RAL, RBV
94  2014 Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution. ART, SMART
95  2014 Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor. COBI, CrCl, DRV, PRT, RTV, Wk
96  2014 Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014. ART, DRV, EFV, IDU, MSM, RAL, RPV
97  2014 Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression. BL
98  2013 Advances in antiretroviral therapy. COBI, DTG, EVG, FDCs, RAL, RIL
99  2013 Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up. GEE
100  2013 Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. CI, MI, PYFU